Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer

Kenichiro Furukawa; Tomoyuki Irino; Rie Makuuchi; Yusuke Koseki; Kenichi Nakamura; Yuhei Waki; Keiichi Fujiya; Hayato Omori; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masanori Terashima

doi:10.1007/s10120-018-00910-y

Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer

Kenichiro Furukawa, Tomoyuki Irino, Rie Makuuchi, Yusuke Koseki, Kenichi Nakamura, Yuhei Waki, Keiichi Fujiya, Hayato Omori, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Masanori Terashima

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Background: Preoperative wait time is affected by various factors, and a certain time is needed before surgery. There is a concern that cancer treatment delay can lead to poor survival. The present study aimed to evaluate the impact of preoperative wait time on survival in patients with clinical stage (cStage) II/III gastric cancer. Methods: The study included patients with cStage II/III primary gastric cancer undergoing surgery between 2002 and 2012. Preoperative wait time was defined as the time from endoscopy for initial diagnosis to surgery. Patients were divided into the following three groups according to wait time: short wait group (≤ 30 days), intermediate wait group (> 30 and ≤ 60 days), and long wait group (> 60 and ≤ 90 days). Patient characteristics and survival were compared among the groups. Results: This study included 467 male (67%) and 229 female (33%) patients, and the median patient age was 67 years. The numbers of cStage II and III patients were 332 (48%) and 364 (52%), respectively. The median wait time was 45 days. The body mass index was lower in the short wait group than in the other groups. A shorter wait time tended to be associated with a more advanced cStage. Although survival was significantly worse in the short wait group than in the long wait group, wait time was not identified as an independent prognostic factor in multivariate analysis. Conclusion: Preoperative wait time up to 90 days does not affect survival in patients with cStage II/III gastric cancer.

Original language	English
Pages (from-to)	864-872
Number of pages	9
Journal	Gastric Cancer
Volume	22
Issue number	4
DOIs	https://doi.org/10.1007/s10120-018-00910-y
Publication status	Published - 2019 Jul 12
Externally published	Yes

Keywords

Gastric cancer
Preoperative wait time
Surgery
Survival

ASJC Scopus subject areas

Oncology
Gastroenterology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10120-018-00910-y

Cite this

@article{997df781378545589d8dc846f9372ec0,

title = "Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer",

abstract = "Background: Preoperative wait time is affected by various factors, and a certain time is needed before surgery. There is a concern that cancer treatment delay can lead to poor survival. The present study aimed to evaluate the impact of preoperative wait time on survival in patients with clinical stage (cStage) II/III gastric cancer. Methods: The study included patients with cStage II/III primary gastric cancer undergoing surgery between 2002 and 2012. Preoperative wait time was defined as the time from endoscopy for initial diagnosis to surgery. Patients were divided into the following three groups according to wait time: short wait group (≤ 30 days), intermediate wait group (> 30 and ≤ 60 days), and long wait group (> 60 and ≤ 90 days). Patient characteristics and survival were compared among the groups. Results: This study included 467 male (67%) and 229 female (33%) patients, and the median patient age was 67 years. The numbers of cStage II and III patients were 332 (48%) and 364 (52%), respectively. The median wait time was 45 days. The body mass index was lower in the short wait group than in the other groups. A shorter wait time tended to be associated with a more advanced cStage. Although survival was significantly worse in the short wait group than in the long wait group, wait time was not identified as an independent prognostic factor in multivariate analysis. Conclusion: Preoperative wait time up to 90 days does not affect survival in patients with cStage II/III gastric cancer.",

keywords = "Gastric cancer, Preoperative wait time, Surgery, Survival",

author = "Kenichiro Furukawa and Tomoyuki Irino and Rie Makuuchi and Yusuke Koseki and Kenichi Nakamura and Yuhei Waki and Keiichi Fujiya and Hayato Omori and Yutaka Tanizawa and Etsuro Bando and Taiichi Kawamura and Masanori Terashima",

note = "Funding Information: Conflict of interest Author MT has received research grants from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical company, Eli Lilly Japan, Ono Pharmaceutical company, Bristol Myers Squib Japan, and Yakult Honsha Co., Ltd. Author EB has received research grants from EIZO Corporation, Kanehara-Shuppan, TERUMO CORPORATION, and EIZAI. Funding Information: Funding This study was funded by National Cancer Center Research and Development Fund (29-4-3).",

year = "2019",

month = jul,

day = "12",

doi = "10.1007/s10120-018-00910-y",

language = "English",

volume = "22",

pages = "864--872",

journal = "Gastric Cancer",

issn = "1436-3291",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer

AU - Furukawa, Kenichiro

AU - Irino, Tomoyuki

AU - Makuuchi, Rie

AU - Koseki, Yusuke

AU - Nakamura, Kenichi

AU - Waki, Yuhei

AU - Fujiya, Keiichi

AU - Omori, Hayato

AU - Tanizawa, Yutaka

AU - Bando, Etsuro

AU - Kawamura, Taiichi

AU - Terashima, Masanori

N1 - Funding Information: Conflict of interest Author MT has received research grants from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical company, Eli Lilly Japan, Ono Pharmaceutical company, Bristol Myers Squib Japan, and Yakult Honsha Co., Ltd. Author EB has received research grants from EIZO Corporation, Kanehara-Shuppan, TERUMO CORPORATION, and EIZAI. Funding Information: Funding This study was funded by National Cancer Center Research and Development Fund (29-4-3).

PY - 2019/7/12

Y1 - 2019/7/12

N2 - Background: Preoperative wait time is affected by various factors, and a certain time is needed before surgery. There is a concern that cancer treatment delay can lead to poor survival. The present study aimed to evaluate the impact of preoperative wait time on survival in patients with clinical stage (cStage) II/III gastric cancer. Methods: The study included patients with cStage II/III primary gastric cancer undergoing surgery between 2002 and 2012. Preoperative wait time was defined as the time from endoscopy for initial diagnosis to surgery. Patients were divided into the following three groups according to wait time: short wait group (≤ 30 days), intermediate wait group (> 30 and ≤ 60 days), and long wait group (> 60 and ≤ 90 days). Patient characteristics and survival were compared among the groups. Results: This study included 467 male (67%) and 229 female (33%) patients, and the median patient age was 67 years. The numbers of cStage II and III patients were 332 (48%) and 364 (52%), respectively. The median wait time was 45 days. The body mass index was lower in the short wait group than in the other groups. A shorter wait time tended to be associated with a more advanced cStage. Although survival was significantly worse in the short wait group than in the long wait group, wait time was not identified as an independent prognostic factor in multivariate analysis. Conclusion: Preoperative wait time up to 90 days does not affect survival in patients with cStage II/III gastric cancer.

AB - Background: Preoperative wait time is affected by various factors, and a certain time is needed before surgery. There is a concern that cancer treatment delay can lead to poor survival. The present study aimed to evaluate the impact of preoperative wait time on survival in patients with clinical stage (cStage) II/III gastric cancer. Methods: The study included patients with cStage II/III primary gastric cancer undergoing surgery between 2002 and 2012. Preoperative wait time was defined as the time from endoscopy for initial diagnosis to surgery. Patients were divided into the following three groups according to wait time: short wait group (≤ 30 days), intermediate wait group (> 30 and ≤ 60 days), and long wait group (> 60 and ≤ 90 days). Patient characteristics and survival were compared among the groups. Results: This study included 467 male (67%) and 229 female (33%) patients, and the median patient age was 67 years. The numbers of cStage II and III patients were 332 (48%) and 364 (52%), respectively. The median wait time was 45 days. The body mass index was lower in the short wait group than in the other groups. A shorter wait time tended to be associated with a more advanced cStage. Although survival was significantly worse in the short wait group than in the long wait group, wait time was not identified as an independent prognostic factor in multivariate analysis. Conclusion: Preoperative wait time up to 90 days does not affect survival in patients with cStage II/III gastric cancer.

KW - Gastric cancer

KW - Preoperative wait time

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85058351777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058351777&partnerID=8YFLogxK

U2 - 10.1007/s10120-018-00910-y

DO - 10.1007/s10120-018-00910-y

M3 - Article

C2 - 30535877

AN - SCOPUS:85058351777

SN - 1436-3291

VL - 22

SP - 864

EP - 872

JO - Gastric Cancer

JF - Gastric Cancer

IS - 4

ER -

Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this